Neuberger Berman Group
OCUL icon

Neuberger Berman Group’s Ocular Therapeutix OCUL Stock Holding History

Neuberger Berman Group’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-51,400
Closed -$213K – 1851
2022
Q3 		$213K Sell
51,400
-150
-0.3% -$756 ﹤0.01% 1710
2022
Q2 		$207K Sell
51,550
-8,960
-15% -$33.8K ﹤0.01% 1745
2022
Q1 		$300K Sell
60,510
-33
-0.1% -$183 ﹤0.01% 1702
2021
Q4 		$422K Buy
60,543
+4
+0% +$31 ﹤0.01% 1601
2021
Q3 		$605K Sell
60,539
-650
-1% -$7.3K ﹤0.01% 1430
2021
Q2 		$868K Sell
61,189
-350
-0.6% -$5.32K ﹤0.01% 1358
2021
Q1 		$1.01M Sell
61,539
-2,051
-3% -$39.5K ﹤0.01% 1311
2020
Q4 		$1.32M Buy
63,590
+100
+0.2% +$1.49K ﹤0.01% 1189
2020
Q3 		$483K Buy
63,490
+30
+0% +$249 ﹤0.01% 1357
2020
Q2 		$529K Buy
63,460
+220
+0.3% +$1.46K ﹤0.01% 1271
2020
Q1 		$313K Hold
63,240
– – ﹤0.01% 1332
2019
Q4 		$250K Sell
63,240
-4,000
-6% -$13.9K ﹤0.01% 1421
2019
Q3 		$204K Hold
67,240
– – ﹤0.01% 1473
2019
Q2 		$296K Buy
67,240
+26,600
+65% +$98.5K ﹤0.01% 1400
2019
Q1 		$161K Sell
40,640
-900
-2% -$3.62K ﹤0.01% 1474
2018
Q4 		$165K Hold
41,540
– – ﹤0.01% 1509
2018
Q3 		$286K Buy
41,540
+2,375
+6% +$14.9K ﹤0.01% 1446
2018
Q2 		$264K Hold
39,165
– – ﹤0.01% 1567
2018
Q1 		$255K Buy
39,165
+5,300
+16% +$29.8K ﹤0.01% 1535
2017
Q4 		$151K Sell
33,865
-4,800
-12% -$24.5K ﹤0.01% 1709
2017
Q3 		$239K Buy
38,665
+8,765
+29% +$56.4K ﹤0.01% 1468
2017
Q2 		$277K Buy
+29,900
New +$289K ﹤0.01% 1433

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Neuberger Berman Group's OCUL Position: Q4 2022 in Review

Neuberger Berman Group sold out of Ocular Therapeutix (OCUL) in Q4 2022, closing a stake of 51,400 shares — an estimated $213K sold.

Neuberger Berman Group first reported a position in OCUL in Q2 2017 and held it in 22 quarters. The position peaked at $1.32M in Q4 2020. 116 funds tracked by Wall St. Rank hold OCUL as of Q4 2022.

  • Neuberger Berman Group reported no remaining Ocular Therapeutix position as of Q4 2022 after selling out during the quarter.
  • Neuberger Berman Group sold 51,400 Ocular Therapeutix shares in Q4 2022, an estimated $213K.
  • Neuberger Berman Group first reported a position in Ocular Therapeutix in Q2 2017 and held it in 22 quarters.
  • Neuberger Berman Group's Ocular Therapeutix position peaked at $1.32M in Q4 2020.
  • 116 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2022.

Based on Neuberger Berman Group's 13F filing for Q4 2022, filed 13 Feb 2023.